E2609

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolism and Elimination

Conditions

Metabolism and Elimination

Trial Timeline

Jun 1, 2013 → Mar 1, 2014

About E2609

E2609 is a phase 1 stage product being developed by Eisai for Metabolism and Elimination. The current trial status is completed. This product is registered under clinical trial identifier NCT01975636. Target conditions include Metabolism and Elimination.

What happened to similar drugs?

5 of 20 similar drugs in Metabolism and Elimination were approved

Approved (5) Terminated (2) Active (15)
cyclosporine micro-emulsionNovartisApproved
Fluvastatin sodiumNovartisApproved
🔄liraglutide + placeboNovo NordiskPhase 3
🔄Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02859207Phase 1Completed
NCT01975636Phase 1Completed
NCT01716897Phase 1Completed

Competing Products

20 competing products in Metabolism and Elimination

See all competitors
ProductCompanyStageHype Score
mRNA-3704ModernaPhase 2
0
E2006EisaiPhase 1
29
AZD3480 + Placebo + Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)AstraZenecaPhase 1
29
Xuezhikang Capsule + Atorvastatin Calcium TabletsAstraZenecaApproved
43
Rabeprazole or Esomeprazole or LanzoprazoleAstraZenecaPre-clinical
26
cyclosporine micro-emulsionNovartisApproved
35
Fluvastatin sodiumNovartisApproved
43
NNC0165-1562 + placeboNovo NordiskPhase 1
29
liraglutideNovo NordiskPhase 1
29
NNC9204-0530 + placeboNovo NordiskPhase 1
29
liraglutide + placeboNovo NordiskPhase 1
29
liraglutide + placebo + liraglutide + placeboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40
Liraglutide 3.0 mg + PlaceboNovo NordiskPhase 3
40
Semaglutide + Placebo (semaglutide)Novo NordiskPhase 3
40
liraglutide + orlistat + placeboNovo NordiskPhase 2
35
NNC 0070-0002-0453 + '2-0453 + placeboNovo NordiskPhase 1
21
NNC0194-0499 + PlaceboNovo NordiskPhase 1
29
Semaglutide + PlaceboNovo NordiskPhase 3
40
liraglutide + placeboNovo NordiskPhase 3
40